Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline
- PMID: 30826525
- DOI: 10.1016/j.breast.2019.02.009
Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline
Abstract
The primary aim of the international advance breast cancer (ABC) guidelines are to guide treatment decisions in many different healthcare settings, but need adaptations due to different access to care. These guidelines are based on the most up-to-date evidence. However, Chinese experts have a different national condition and policies to face. The Chinese Anti-Cancer Association Committee of Breast Cancer Society guideline (CBCS guideline) is to guide treatments and to reflect unmet needs of Chinese breast cancer patients. Although, most of the recommendations in the two guidelines are the same, some of them are different. In this article, with regard to country-specific peculiarities, a working group of Chinese breast cancer experts compare the similarities and differences between the ABC guideline and CBCS guideline and commented on the voting results of the ABC panelists. We also discuss why these differences exist, such as lack of access, different tumor biology and epidemiology, and even different culture. The money which patients have to pay out of pocket for their medical cost and the availability of drugs lie at the heart of the issues of guideline differences.
Keywords: ABC4 guideline; Advance breast cancer; CBCS guideline.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17. Breast. 2017. PMID: 28822332
-
4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.Geburtshilfe Frauenheilkd. 2018 May;78(5):469-480. doi: 10.1055/a-0594-2243. Epub 2018 Jun 4. Geburtshilfe Frauenheilkd. 2018. PMID: 29880982 Free PMC article.
-
New Zealand experience with implementation of the ESO-ESMO consensus guidelines for advanced breast cancer-report of achievements and lessons learned.Breast. 2022 Jun;63:108-112. doi: 10.1016/j.breast.2022.03.017. Epub 2022 Mar 25. Breast. 2022. PMID: 35366504 Free PMC article.
-
National consensus in China on diagnosis and treatment of patients with advanced breast cancer.Ann Transl Med. 2015 Oct;3(17):242. doi: 10.3978/j.issn.2305-5839.2015.09.47. Ann Transl Med. 2015. PMID: 26605288 Free PMC article. Review.
-
[A consensus statement on the breast-conserving surgery of early-stage breast cancer (2019)].Zhonghua Wai Ke Za Zhi. 2019 Feb 1;57(2):81-84. doi: 10.3760/cma.j.issn.0529-5815.2019.02.001. Zhonghua Wai Ke Za Zhi. 2019. PMID: 30704207 Chinese.
Cited by
-
Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis.Oncol Lett. 2020 Oct;20(4):92. doi: 10.3892/ol.2020.11953. Epub 2020 Aug 6. Oncol Lett. 2020. PMID: 32831911 Free PMC article.
-
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data.Ther Adv Drug Saf. 2022 Dec 23;13:20420986221146411. doi: 10.1177/20420986221146411. eCollection 2022. Ther Adv Drug Saf. 2022. PMID: 36582188 Free PMC article.
-
Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.Front Oncol. 2021 Aug 30;11:690658. doi: 10.3389/fonc.2021.690658. eCollection 2021. Front Oncol. 2021. PMID: 34527574 Free PMC article.
-
Long-Term Results of Partial Breast Irradiation After Breast-Conserving Surgery for Early Stage Breast Cancer: A Prospective Phase II Trial in China.Front Oncol. 2020 Sep 2;10:550950. doi: 10.3389/fonc.2020.550950. eCollection 2020. Front Oncol. 2020. PMID: 32984062 Free PMC article.
-
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.Breast Cancer (Dove Med Press). 2024 Apr 10;16:181-197. doi: 10.2147/BCTT.S438366. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 38617842 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical